GlobalData on MSN13d
Can-Fite BioPharma secures US patent for Namodenoson
Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.
Can-Fite BioPharma announces U.S. patent office granted patent to Namodenoson
Can-Fite BioPharma (CANF) announced that its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US ...
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Gan, ...